

16 July 2024



## DIRECTOR NOMINATION CLOSING DATE

**DUNEDIN, New Zealand** - Cancer diagnostics company, Pacific Edge Limited (NZX, ASX: PEB), advises that its Annual Shareholder Meeting will be held on Tuesday 24 September 2024 starting at 1pm in Auckland.

For the purposes of Listing Rule 2.3.2, Pacific Edge advises that the closing date for Director nominations is Tuesday 30 July 2024. All nominations must be received by 4.00pm on the closing date.

Nominations may only be made by a shareholder entitled to attend and vote at the Annual Shareholder Meeting and must be accompanied by a consent in writing by the nominated person.

Nominations should be either emailed to [investors@pacificedge.co.nz](mailto:investors@pacificedge.co.nz) or addressed to:

Director Nominations  
Pacific Edge Limited  
PO Box 56  
Dunedin 9016  
New Zealand

Further details, including proxy voting forms and details of any resolutions will be provided in the Notice of Meeting, which will be sent to shareholders prior to the meeting.

Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.

### For more information:

#### Investors:

Dr Peter Meintjes  
Chief Executive  
Pacific Edge  
P: 022 032 1263

#### Media:

Richard Inder  
The Project  
P: +64 21 645 643

## OVERVIEW

**Pacific Edge:** [www.pacificedgedx.com](http://www.pacificedgedx.com)

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

**Cxbladder:** [www.cxbladder.com](http://www.cxbladder.com)

Cxbladder is a urine-based genomic biomarker test optimized for the detection and surveillance of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications for primary detection, surveillance, adjudication of atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous ongoing and planned clinical studies to generate an ever-increasing body of clinical utility evidence supporting adoption and use in the clinic to improve patient health outcomes. Cxbladder has been trusted by over 4,400 US urologists in the diagnosis and management of more than 100,000 patients, including the option for in-home sample collection. In New Zealand, Cxbladder is accessible to 75% of the population via public healthcare and all residents have the option of buying the test online.